AS SEEN IN
Recent Posts
Managing Persistence Problems -Starting and Stopping GLP-1 Medications
Most people don’t like taking medications – especially longterm. In fact, medication fatigue where individuals stop taking a new medication, like a statin or blood pressure pill, is commonplace. But the number of individuals stopping GLP-1 medications is especially concerning as studies show that over 50% of GLP-1 users discontinue the medication by 1 year…
Can Treating Obesity Improve Women’s Health and Fertility?
I recently had the exciting opportunity to educate gynecologists and fertility specialists throughout India on the role of semaglutide in women’s reproductive health. This allowed me to take a deep dive into the research and medical data answering the question: can obesity treatments improve women’s health outcomes and fertility rates? The answer is a resounding…
‘Treat to Target’ Considerations in Obesity Care
As the field of obesity medicine matures, clinicians and patients are asking: “What is the treatment target?” achievement of a targeted percentage weight loss? improved body mass index (BMI) or waist circumference? better function and quality of life? remission of weight-related complications? ability to taper or discontinue medications for other chronic disease treatments? or –…
Ripple Effects of GLP-1 Obesity Medications on Society
The effects of game-changing GLP-1 medications on individuals and society was the topic of my recent keynote address at the Northwestern University Alumni Association event in Naples, Florida. Individuals on GLP-1 medications are changing how they eat, shop, live, play and get their healthcare and companies are taking notice. We usually think of big tech…